基孔肯雅病毒样颗粒疫苗安全性与耐受性随机临床试验
这项随机、安慰剂对照、双盲2期试验在基孔肯雅热流行区纳入400名健康成人,按1:1接受2剂CHIKV VLP疫苗(20 µg)或安慰剂,间隔28天,随访72周。疫苗耐受性良好,未发现与疫苗相关的严重不良事件;第二次接种后4周中和抗体EC50 GMT疫苗组为2005,安慰剂组为43(P < .001),免疫应答持续至72周。
要点
- CHIKV VLP疫苗在流行区健康成人中耐受性良好,无疫苗相关严重不良事件。
- 第二次接种后4周疫苗组中和抗体EC50 GMT达2005,显著高于安慰剂组的43。
- 免疫应答持久性维持至接种后72周,仍需3期试验评估临床效力。
核心结论
- 在基孔肯雅热流行区的健康成人中,CHIKV VLP疫苗相比安慰剂显示出安全性和耐受性。
- 需开展3期临床试验评估该疫苗的临床效力。
研究设计与样本
- 随机、安慰剂对照、双盲2期临床试验,在6个门诊临床研究站点开展,站点位于海地、多米尼加共和国、马提尼克、瓜德罗普和波多黎各。
- 共纳入400名18至60岁健康成人,随机1:1接受2剂肌肉注射(间隔28天),疫苗组20 µg(n=201),安慰剂组(n=199),随访72周。
- 首次入组日期为2015年11月18日,末次研究访视为2018年3月6日。
主要发现
- 400名随机参与者(平均年龄35岁;199名[50%]女性)中,393名(98%)完成主要安全性分析。
- 所有注射耐受良好;16例与研究药物无关的严重不良事件中,疫苗组4例患者发生4例(25%),安慰剂组11例患者发生12例(75%)。
- 16例可能与药物相关的轻至中度非征集不良事件中,疫苗组8例患者发生12例(75%),安慰剂组3例患者发生4例(25%);所有可能相关不良事件均无临床后遗症地缓解。
- 基线时疫苗组中和抗体EC50几何平均滴度(GMT)为46(95% CI,34-63),安慰剂组为43(95% CI,32-57),组间无显著差异。
- 首次接种后8周,疫苗组EC50 GMT为2005(95% CI,1680-2392),安慰剂组为43(95% CI,32-58;P < .001);免疫应答持久性维持至接种后72周。
临床怎么用
- 该2期试验提示CHIKV VLP疫苗在流行区成人中安全且耐受性良好,并诱导高滴度中和抗体。
- 当前证据尚不足以支持临床效力结论,应用需等待3期临床试验结果。
局限性
- 原文未报告临床效力终点,需3期试验评估。
- 原文未报告疫苗对基孔肯雅病毒感染的保护效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Chikungunya virus (CHIKV) is a mosquito-borne Alphavirus prevalent worldwide. There are currently no licensed vaccines or therapies. OBJECTIVE: To evaluate the safety and tolerability of an investigational CHIKV virus-like particle (VLP) vaccine in endemic regions. DESIGN, SETTING, AND PARTICIPANTS: This was a randomized, placebo-controlled, double-blind, phase 2 clinical trial to assess the vaccine VRC-CHKVLP059-00-VP (CHIKV VLP). The trial was conducted at 6 outpatient clinical research sites located in Haiti, Dominican Republic, Martinique, Guadeloupe, and Puerto Rico. A total of 400 healthy adults aged 18 through 60 years were enrolled after meeting eligibility criteria. The first study enrollment occurred on November 18, 2015; the final study visit, March 6, 2018. INTERVENTIONS: Participants were randomized 1:1 to receive 2 intramuscular injections 28 days apart (20 µg, n = 201) or placebo (n = 199) and were followed up for 72 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was the safety (laboratory parameters, adverse events, and CHIKV infection) and tolerability (local and systemic reactogenicity) of the vaccine, and the secondary outcome was immune response by neutralization assay 4 weeks after second vaccination. RESULTS: Of the 400 randomized participants (mean age, 35 years; 199 [50%] women), 393 (98%) completed the primary safety analysis. All injections were well tolerated. Of the 16 serious adverse events unrelated to the study drugs, 4 (25%) occurred among 4 patients in the vaccine group and 12 (75%) occurred among 11 patients in the placebo group. Of the 16 mild to moderate unsolicited adverse events that were potentially related to the drug, 12 (75%) occurred among 8 patients in the vaccine group and 4 (25%) occurred among 3 patients in the placebo group. All potentially related adverse events resolved without clinical sequelae. At baseline, there was no significant difference between the effective concentration (EC50)-which is the dilution of sera that inhibits 50% infection in viral neutralization assay-geometric mean titers (GMTs) of neutralizing antibodies of the vaccine group (46; 95% CI, 34-63) and the placebo group (43; 95% CI, 32-57). Eight weeks following the first administration, the EC50 GMT in the vaccine group was 2005 (95% CI, 1680-2392) vs 43 (95% CI, 32-58; P < .001) in the placebo group. Durability of the immune response was demonstrated through 72 weeks after vaccination. CONCLUSIONS AND RELEVANCE: Among healthy adults in a chikungunya endemic population, a virus-like particle vaccine compared with placebo demonstrated safety and tolerability. Phase 3 trials are needed to assess clinical efficacy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02562482.
引用
- Chen GL, Coates EE, Plummer SH, et al. Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial. JAMA. 2020. PMID: 32286643. doi:10.1001/jama.2020.2477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。